Skip to Main Content
Table 2—

Changes of characteristics from baseline to 6 months after treatment with either rosiglitazone in 30 subjects or placebo in 34 subjects

RosiglitazonePlacebo
Body weight 3.0 ± 2.4§ −0.4 ± 1.9 
BMI 1.20 ± 1.00§ −0.18 ± 0.79 
Systolic blood pressure −0.3 ± 15.7* −8.1 ± 16.3 
Diastolic blood pressure −0.4 ± 8.0 −1.1 ± 7.4 
Fasting plasma glucose −10.6 ± 41.0 17.8 ± 58.5 
Fasting plasma insulin −1.07 ± 4.87 −1.16 ± 4.72 
Insulin resistance −0.19 ± 0.47* 0.04 ± 0.60 
Insulin secretion −1.20 ± 12.80 −3.11 ± 8.31 
HbA1c −0.7 ± 1.0 0.4 ± 1.3 
RosiglitazonePlacebo
Body weight 3.0 ± 2.4§ −0.4 ± 1.9 
BMI 1.20 ± 1.00§ −0.18 ± 0.79 
Systolic blood pressure −0.3 ± 15.7* −8.1 ± 16.3 
Diastolic blood pressure −0.4 ± 8.0 −1.1 ± 7.4 
Fasting plasma glucose −10.6 ± 41.0 17.8 ± 58.5 
Fasting plasma insulin −1.07 ± 4.87 −1.16 ± 4.72 
Insulin resistance −0.19 ± 0.47* 0.04 ± 0.60 
Insulin secretion −1.20 ± 12.80 −3.11 ± 8.31 
HbA1c −0.7 ± 1.0 0.4 ± 1.3 

Data are means ± SD.

*

P < 0.1;

P < 0.05;

P < 0.005;

§

P < 0.0005 compared with the placebo group by student’s t test.

Close Modal

or Create an Account

Close Modal
Close Modal